Treace Medical price target raised to $8.40 from $7 at Truist

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

TipRanks

Thu, Dec 19, 2024, 5:37 AM 1 min read

Truist raised the firm’s price target on Treace Medical (TMCI) to $8.40 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.

Pick the best stocks and maximize your portfolio:

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on TMCI: